Your session is about to expire
← Back to Search
Stem Cell Therapy
Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Patients With Thoracic Spinal Cord Injury
Phase 1 & 2
Waitlist Available
Research Sponsored by StemCells, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up one year after transplant
Awards & highlights
No Placebo-Only Group
Summary
This study will evaluate the effect of single transplantation of HuCNS-SC cells into the thoracic spinal cord of patients with sub-acute spinal cord injury.
Eligible Conditions
- Spinal Cord Injury
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ one year after transplant
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one year after transplant
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Types and frequencies of adverse events and serious adverse events
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: HuCNS-SC cellsExperimental Treatment1 Intervention
Single dose intramedullary administration of HuCNS-SC cells
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
HuCNS-SC cells
2012
Completed Phase 2
~40
Find a Location
Who is running the clinical trial?
StemCells, Inc.Lead Sponsor
9 Previous Clinical Trials
83 Total Patients Enrolled
Stephen Huhn, MDStudy ChairStemCells, Inc.
9 Previous Clinical Trials
397 Total Patients Enrolled